Boehringer Ingelheim chairman Prof Andreas Barner

June 27, 2016

Multinational pharmaceutical giants Sanofi and Boehringer Ingelheim announced on Monday they have signed contracts, a significant milestone towards the planned “swap” of the French and German companies’ animal health and consumer health care arms.

When the deal is completed – expected at the end of 2016 – Boehringer Ingelheim’s consumer health care business will be transferred to Sanofi, and Sanofi’s subsidiary Merial will be transferred to Boehringer Ingelheim.

Sanofi would integrate Boehringer Ingelheim’s consumer health care business in all countries except China.

The transaction includes a cash payment to Sanofi of almost $AUD 7 billion to reflect the difference in value of the two businesses.

“This is a win for Boehringer Ingelheim and Sanofi alike,” Boehringer Ingelheim chairman Prof Andreas Barner said.

“Moreover, it is one of the most significant steps in our corporate history. It demonstrates the consistent orientation of our business towards innovation-driven sectors.

“As a research-based pharmaceutical company, we will substantially enhance our position in the future market for animal health and will prospectively be one of the largest global players in this segment.”

Boehringer Ingelheim’s consumer healthcare business includes the brands Buscopan, Dulcolax, Pharmaton, Mucosolvan and Bisolvon.

Merial’s animal health products include Frontline, Heartgard, NexGard, Broadline, Purevax, Vaxxitek, Eprinex, Ivomec, Longrange, Circovac and GastroGard.

Footnote: Buscopan is manufactured from an alkaloid extracted from duboisia grown in the South Burnett. However, a Boehringer Ingelheim spokesman has previously told southburnett.com.au the company’s operations in Kingaroy would not be affected by the transaction.


 

Leave a Reply

Your email address will not be published.